- Home
- AMBC vs TRVI Comparison
AMBC vs TRVI Comparison
Compare AMBC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- TRVI
- Stock Information
- Founded
- AMBC 1971
- TRVI 2011
- Country
- AMBC United States
- TRVI United States
- Employees
- AMBC N/A
- TRVI N/A
- Industry
- AMBC Property-Casualty Insurers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- TRVI Health Care
- Exchange
- AMBC Nasdaq
- TRVI Nasdaq
- Market Cap
- AMBC 411.3M
- TRVI 383.4M
- IPO Year
- AMBC 1991
- TRVI 2019
- Fundamental
- Price
- AMBC $8.18
- TRVI $6.61
- Analyst Decision
- AMBC Strong Buy
- TRVI Strong Buy
- Analyst Count
- AMBC 2
- TRVI 8
- Target Price
- AMBC $17.00
- TRVI $17.56
- AVG Volume (30 Days)
- AMBC 797.5K
- TRVI 1.3M
- Earning Date
- AMBC 05-12-2025
- TRVI 05-08-2025
- Dividend Yield
- AMBC N/A
- TRVI N/A
- EPS Growth
- AMBC N/A
- TRVI N/A
- EPS
- AMBC N/A
- TRVI N/A
- Revenue
- AMBC $240,754,000.00
- TRVI N/A
- Revenue This Year
- AMBC N/A
- TRVI N/A
- Revenue Next Year
- AMBC N/A
- TRVI N/A
- P/E Ratio
- AMBC N/A
- TRVI N/A
- Revenue Growth
- AMBC 90.76
- TRVI N/A
- 52 Week Low
- AMBC $6.33
- TRVI $2.30
- 52 Week High
- AMBC $18.45
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- AMBC 55.73
- TRVI 56.38
- Support Level
- AMBC $7.92
- TRVI $6.37
- Resistance Level
- AMBC $8.58
- TRVI $7.24
- Average True Range (ATR)
- AMBC 0.25
- TRVI 0.42
- MACD
- AMBC 0.11
- TRVI -0.01
- Stochastic Oscillator
- AMBC 68.25
- TRVI 50.38
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.